Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03537482 · ClinicalTrials.gov registry record · Early Phase 1
APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies
A Early Phase 1 study of Hematologic Malignancies, sponsored by Ascentage Pharma Group.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 90
- Enrollment target
- 5
- Study locations
NCT03537482 is a Early Phase 1 study of Hematologic Malignancies that is actively recruiting participants, run by Ascentage Pharma Group. The registered enrollment target is 90 participants, below the 2,710-participant average among 45 other Hematologic Malignancies trials with a reported enrollment target (97% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT03537482, a Early Phase 1 study of Hematologic Malignancies, is actively recruiting participants, sponsored by Ascentage Pharma Group.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 90 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a multi-center, single-agent, open-label, Phase I study of APG-2575. The study consists of the dose escalation stage and the dose expansion stage.
Conditions Studied
Interventions
- DRUG APG-2575
Study Locations (5)
Victoria
- St. Vincent Hospital - Fitzroy
- Epworth Healthcare - Richmond
Florida
- Mayo Clinic - Jacksonville
North Carolina
- Duke Unviersity - Durham
Texas
- MDACC - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2018-08-07 |
| Est. Completion | 2025-02-15 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03537482
The ClinicalTrials.gov registry entry for NCT03537482 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,710-participant average among 45 other Hematologic Malignancies trials with a reported enrollment target (97% lower). The listed sponsor is Ascentage Pharma Group, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hematologic Malignancies appearing as the primary indexed condition, and to 1 intervention - of which APG-2575 is the first listed.
NCT03537482 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Victoria, Florida, North Carolina.
Frequently Asked Questions
What is clinical trial NCT03537482 about?
NCT03537482 is a clinical study titled "APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies". This is a multi-center, single-agent, open-label, Phase I study of APG-2575. The study consists of the dose escalation stage and the dose expansion stage.
What is the current status of trial NCT03537482?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 90 participants. The study started on 2018-08-07. Estimated completion is 2025-02-15.
What conditions does trial NCT03537482 study?
This clinical trial studies the following conditions: Hematologic Malignancies.
What interventions are being tested in trial NCT03537482?
The interventions under investigation include: APG-2575 (DRUG).
Who is sponsoring clinical trial NCT03537482?
This trial is sponsored by Ascentage Pharma Group, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03537482 being conducted?
This trial has 5 study locations across Florida, North Carolina, Texas, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematologic Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
RECRUITING · Phase 1
-
Post-Transplant Cyclophosphamide in Patients Aged >/= 65 Years Undergoing Haploidentical Transplant
RECRUITING · Phase 1
-
A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies
RECRUITING · Phase 1
-
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
RECRUITING · Phase 1
-
Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation
RECRUITING · Phase 2
-
Prophylactic TCRaB+ and CD19+ Depleted Donor Lymphocyte Infusion After Allogeneic Stem Cell Transplant in High-Risk Patients With Hematologic Malignancies
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.